The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design

Duke University, Durham, North Carolina, United States
American heart journal (Impact Factor: 4.56). 04/2006; 151(4):786.e1-10. DOI: 10.1016/j.ahj.2005.11.004
Source: PubMed

ABSTRACT The risk of atherothrombosis is a large health care burden worldwide. With its global prevalence, there is a need to understand all the associated risk factors, both old and new, and their interdependencies in the development of this complex disease leading to myocardial infarction, ischemic stroke, and vascular death and, thus, the major cause of mortality throughout the world.
The REACH Registry sought to compile an international data set to extend our knowledge of atherothrombotic risk factors and ischemic events in the outpatient setting. The Registry will recruit approximately 68,000 outpatients in 44 countries across 6 major regions (Latin America, North America, Europe, Asia, the Middle East, and Australia) from >5000 physician outpatient practices. Patients aged > or =45 years with at least 3 atherothrombotic risk factors or documented cerebrovascular, coronary artery, or peripheral arterial disease will be enrolled. Medical history, risk factors, demographic information, and management will be collected at baseline, and clinical events that occur during the follow-up period of up to 2 years in duration will be recorded.
The REACH Registry offers an opportunity to provide a better understanding of the prevalence and clinical consequences of atherothrombosis in the outpatient setting in a wide range of patients from different parts of the world.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of peripheral arterial disease (PAD) among young and middle-aged adults can be significant, but no previous study has examined the prognosis and the associated health care cost of the disease in this population. We evaluated the clinical and economic burden of PAD in patients from a large claims database to clarify the effect of the disease on a relatively young working Japanese population.
    Clinical Therapeutics 07/2014; 36(8). DOI:10.1016/j.clinthera.2014.06.013 · 2.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Characteristics of stroke cases, acute stroke care, and outcomes after stroke differ according to geographical and cultural background. To provide epidemiological and clinical data on stroke care in South Korea, we analyzed a prospective multicenter clinical stroke registry, the Clinical Research Center for Stroke-Fifth Division (CRCS-5). Patients were 58% male with a mean age of 67.2±12.9 years and median National Institutes of Health Stroke Scale score of 3 [1-8] points. Over the 6 years of operation, temporal trends were documented including increasing utilization of recanalization treatment with shorter onset-to-arrival delay and decremental length of stay. Acute recanalization treatment was performed in 12.7% of cases with endovascular treatment utilized in 36%, but the proportion of endovascular recanalization varied across centers. Door-to-IV alteplase delay had a median of 45 [33-68] min. The rate of symptomatic hemorrhagic transformation (HT) was 7%, and that of any HT was 27% among recanalization-treated cases. Early neurological deterioration occurred in 15% of cases and were associated with longer length of stay and poorer 3-month outcomes. The proportion of mRS scores of 0-1 was 42% on discharge, 50% at 3 months, and 55% at 1 year after the index stroke. Recurrent stroke up to 1 year occurred in 4.5% of patients; the rate was higher among older individuals and those with neurologically severe deficits. The above findings will be compared with other Asian and US registry data in this article.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Atherothrombose führt mit ihren Manifestationsformen Herz- und Hirninfarkt sowie vaskulärer Tod die Morbiditäts- und Mortalitätsstatistiken an. Risikopersonen gilt es zu erfassen. Bewährt hat sich das Screening auf PAVK mit dem Knöchel-Arm-Index (ABI), der sich als Prädiktor atherothrombotischer Ereignisse auch bei asymptomatischen Patienten erwiesen hat. Jeder Patient mit Atherothrombosemanifestation ist ein Hochrisikopatient. Bei PAVK besteht ein hohes Risiko für Herz- und Hirninfarkt. Diese Patienten sollten daher so umfassend wie KHK- oder Schlaganfallpatienten behandelt werden. Zum Risikomanagement gehört immer eine medikamentöse (Sekundär-) Prävention mit Thrombozytenfunktionshemmern (TFH), bei niedrigem Risiko mit ASS. Clopidogrel empfehlen aktuelle Therapieleitlinien als Dauergabe bei symptomatischer PAVK und bei Patienten mit hohem Risiko für Schlaganfall und gleichzeitiger asymptomatischer PAVK sowie in Kombination mit ASS über mindestens 9 (bis 12) Monate nach ACS sowie PCI.
    Clinical Research in Cardiology Supplements 01/2007; 2(4).